Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens

Rok, strany: 2019, 301 - 307

A score model based on clinical characteristics in advanced hepatocellular carcinoma (HCC) patients treated with systemic chemotherapy of oxaliplatin-containing regimens was established to evaluate progression-free survival (PFS) and overall survival (OS). Thirty HCC patients eligible for radical resection were involved in the retrospective study, and these were divided into the good response group (complete response (CR)/partial response (PR) and the poor response group (stable disease (SD)/progression disease (PD). The median PFS and OS were compared in the two groups. PFS and OS combined with clinical characteristics were evaluated by univariate and multivariate analyses. The score model was defined with 1 score for each characteristic, and score model cut-off values were determined by the receiver operating characteristic curve (ROC) which describes treatment response. The median PFS was 10 and 2 months (p<0.001), and the median OS was 13 and 4 months (p=0.011) for the CR/PR and SD/PD groups, respectively. The score of 1 was the optimal cutoff value, with sensitivity ranging from 52.6 to 63.2% and specificity from 81.8 to 100% (AUC= 0.773, p=0.014). The median PFS for good and poor response groups was 9 months and 1month (p<0.001) and the median OS was 22 and 3months at p<0.001, respectively. Patients with scores above 1 had poor response, with median 3 months OS and 1 month PFS, and patients with scores of 0 and 1 established good response, with median 22 months OS and 9 months PFS, respectively.

ISO 690:

Qian, L., Dong, Y., Zhao, L., Zhao, H., Cui, J., Wang, N. 2019. Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens. In NEOPLASMA, vol. 66, no.2, pp. 301-307. 0028-2685.

APA:

Qian, L., Dong, Y., Zhao, L., Zhao, H., Cui, J., Wang, N. (2019). Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens. NEOPLASMA, 66(2), 301-307. 0028-2685.